Jensigamet Sustained-Release Tablet 10/1000mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
MFDS item code 202300147 · Approved 2023.01.06
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication assists in blood sugar control for adult patients with type 2 diabetes who are suitable for combined treatment with dapagliflozin and metformin, alongside diet and exercise. Particularly in patients whose blood sugar is not adequately controlled and have cardiovascular disease or risk factors, caution must be taken by referring to expert guidelines regarding the impact of dapagliflozin on the occurrence of cardiovascular events. Overall, this medication is used to effectively improve blood sugar management in type 2 diabetes patients.
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. This medication must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication helps to control blood sugar. Rarely, it may cause a serious condition called lactic acidosis, which can be life-threatening, so caution is required during use. Also, when used with other diabetes medications like insulin or sulfonylureas, hypoglycemia may occur, requiring careful monitoring. Patients with moderate to severe kidney function impairment, dehydration, severe infections, or heart diseases should not take this medication. It should also be temporarily discontinued before and after surgery or radiological examinations, and can only be resumed after confirming normal kidney function. Pregnant or breastfeeding women should not use this medication. This medication can cause decreased fluid volume or low blood pressure; therefore, especially elderly patients or those taking diuretics should regularly check blood pressure and kidney function. Genital infections or urinary tract infections may occur during treatment, so consult a doctor immediately if symptoms arise. Vitamin B12 levels may decrease, so if taken long-term, regular vitamin B12 tests are recommended. Alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid it. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking other medications. In case of overdose, visit a medical facility immediately for appropriate treatment. The safety and efficacy of this medication have not been established in children, so it should not be used in this population. Dizziness may occur during treatment, so caution is advised when driving or operating machinery. Finally, this medication should be stored out of reach of children and kept in the original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is recommended to keep the storage temperature between 1°C and 30°C at room temperature.
Yellow, biconvex, oval-shaped sustained-release film-coated tablet
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.